Softwr

Healthcare · head to head

Paige vs Rx30

Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite
Rx30 logo

Rx30

Healthcare

Long-established pharmacy management system for independents and small chains

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.; Rx30 shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
  • They diverge on capability: Paige covers Paige Prostate Detect, Rx30 covers Prescription processing.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Paige and Rx30 actually diverge.

Attributes where Paige and Rx30 differ
AttributePaigeRx30
PlatformsWeb, Cloud, On-premiseWindows, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

Only in Rx30

  • Prescription processing
  • Claims adjudication
  • Inventory and purchasing
  • Point of sale
  • Delivery management
  • Clinical documentation

What people use each for

The jobs each tool is most often brought in to do.

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Rx30
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Rx30
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Rx30
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Rx30

Rx30

  • Independent pharmacies and small chains wanting a mature, widely-supported systemnot Paige
  • Operations relying on a broad set of wholesaler and PBM interfacesnot Paige
  • Pharmacies with significant front-end retail alongside dispensingnot Paige
  • Multi-store independents needing consistency across locationsnot Paige

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Rx30

  • Shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
  • The interface shows its age against newer entrants, and this is the most common objection in demonstrations
  • Pricing is not published, and total cost including hardware and interfaces needs to be requested explicitly
  • Windows-centric, with a cloud story less developed than newer competitors
  • US-only, tied to US insurance and regulatory requirements

Pricing, plan by plan

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Rx30

On request
  • Rx30$undefined/month
    • Prescription processing
    • Claims adjudication
    • Inventory

Which should you pick?

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Choose Rx30 if

  • You need prescription processing.
  • You work on Windows, Web.
  • You also want claims adjudication.
Rx30 review

Questions people ask

Is Paige or Rx30 better?
Neither clearly leads. Paige starts at On request and Rx30 at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Paige or Rx30?
Paige starts at On request and Rx30 at On request.
Does Paige or Rx30 run on more platforms?
Paige runs on Web, Cloud, On-premise. Rx30 runs on Windows, Web.
What is Paige best used for?
Paige is most often used for a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable, a pathology department already digitised that wants a documented safety net against missed small foci of cancer, a hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting, a pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability. Of those, a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable and a pathology department already digitised that wants a documented safety net against missed small foci of cancer are not what Rx30 is typically brought in for.
What can Paige do that Rx30 cannot?
Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications. Rx30 covers Prescription processing, Claims adjudication, Inventory and purchasing, Point of sale.

Answered from the vendors’ own pages

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Rx30: Is Rx30 the same company as PioneerRx?

Both are owned by RedSail Technologies. They are sold as separate products to overlapping markets, but roadmap decisions sit with one company, which is worth knowing before treating them as independent options.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Rx30: What does it cost?

Not published. Request the total including hardware, interfaces and training rather than the monthly software fee.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Rx30: Why do pharmacies stay on it?

Installed base maturity. The interfaces to wholesalers, PBMs and hardware are long established, and those are the things that quietly stop a pharmacy working when they break.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Rx30: How does it compare to PioneerRx?

PioneerRx is more aggressively developed around clinical services. Rx30 has the larger legacy base and broader front-end retail heritage. Same owner, different emphasis.

Rx30: Is it suitable for a small chain?

Yes, and that is one of its stronger cases. Multi-store consistency is better handled here than by the systems aimed purely at single independents.

Share

Related pages

More on Paige

More on Rx30

Keep looking

Other head to heads